LEO Pharma announced today that it received FDA approval for its Adbry injection treatment for moderate-to-severe atopic dermatitis. Ballerup, Denmark-based LEO Pharma designed its Adbry injection for treating atopic dermatitis in adults aged 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. According […]
Leo Pharma
Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
Leo Pharma and Portal Instruments this week announced a global collaboration and license agreement to develop a needle-free drug delivery system. Through the agreement, Leo Pharma’s investigational and approved medicines will be used in combination with Portal’s needle-free drug delivery system. Portal’s needle-free jet injector platform allows patients to self-administer biologics without needles. It features […]
